Paul Maurin

Counsel

Paris + 33.1.56.59.39.13

Contact

Partager

Paul Maurin intervient sur les aspects français et transfrontaliers des opérations de marchés de capitaux, de fusions acquisitions (public et private M&A) et de capital risque du Cabinet.

Il accompagne ainsi des entreprises à fort potentiel de croissance, cotées ou non, ainsi que leurs actionnaires dirigeants, industriels et financiers. Il intervient notamment dans les secteurs des nouvelles technologies (Contentsquare, Doctolib, Ledger, Agicap), des biotech/medtech (Adocia, Carmat, Cellectis, Nanobiotix, Median Technologies) et des énergies renouvelables (Arverne Group, Voltalia). Il assiste ces entreprises tout au long de leur développement, depuis leur création jusqu’à leur cession ou leur introduction en bourse. Paul Maurin conseille également régulièrement des sociétés cotées en matière de levées de fonds, de communication financière, de gouvernance et de rémunération des dirigeants.

Parmi ses opérations récentes et représentatives figurent les introductions en bourse en France de Deezer, d’Arverne Group (dans les deux cas, via un de SPAC), de Tikehau Capital et de Voltalia, ainsi qu’aux États Unis de Nanobiotix; les levées de fonds de sociétés privées (Agicap, Doctolib, Ekimetrics, Ledger, ManoMano) et d’émetteurs cotés sur Euronext (Adocia, Carmat, Voltalia) ou le Nasdaq (Cellectis, Nanobiotix); les cessions d’Amolyt à AstraZeneca, de Silicon Mobility à Intel et de Zelros à Earnix; ainsi que l’acquisition du groupe Magimix par Lavafields ou d’Helexia par Voltalia .

Expérience

  • BioMarin acquires Amicus Therapeutics for $4.8 billionJones Day is advising BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) in its $4.8 billion acquisition of Amicus Therapeutics (Nasdaq: FOLD).
  • Theranexus completes €7.8 million rights issueJones Day represented Theranexus SAS, a pharmaceutical company specializing in rare neurological diseases, listed on Euronext Growth Paris, in connection with its €7.8 million rights issue of new shares.
  • Gojob raises €120 million in strategic investment by PersolJones Day advised Gojob, a pioneer in inclusive temporary staffing and artificial intelligence-based recruitment technology, and its shareholders, in connection with a €120 million strategic investment by Persol, Japan's second-largest temporary staffing company.
  • Dalcq acquires Umami MagimixJones Day has advised Dalcq SA and its main shareholder Lavafields Group, a Belgian household appliances manufacturer, on the acquisition of all shares of Umami Magimix SAS, a French cookware company, from Umami Bidco Sàrl, which is itself controlled by Ardian and Hameur.
  • Median Technologies completes €23.9 million share capital increaseJones Day represented Median Technologies SA, a leading provider of AI-based image analyses and central imaging services for oncology drug developers listed on Euronext Growth Paris, in connection with its €23.9 million share capital increase through a public offering with priority period to institutional and retail investors and a private placement with qualified investors.
  • Gimv invests in AlpineJones Day advised Gimv in the acquisition and financing of a majority stake in Alpine, one of the leading international consumer brands providing passive hearing protection solutions, from Vendis Capital, the founders and management team.
  • Oscar sells Olféo to EkinopsJones Day advised the management and shareholders of Oscar (Olféo group), a French provider of Secure Service Edge cybersecurity software and web security gateways, in connection with the sale of the company to Ekinops, a French supplier of open and interoperable telecommunications solutions.
  • Zelros sold to EarnixJones Day advised the management and shareholders of Zelros SAS, a pioneer in Generative AI for insurers and banks, in connection with the sale of the Company to Earnix, Inc., a U.S. company that develops a dynamic AI platform for insurance.
  • Wall Family Enterprise sells WF Education GroupJones Day advised Wall Family Enterprise, Inc. in the sale of WF Education Group to Commercial Services Group.
  • CARMAT completes €9.7 million share capital increaseJones Day represented CARMAT SA, the designer and developer of the world's most advanced total artificial heart listed on Euronext Growth Paris, in connection with its €9.7 million share capital increase without preferential subscription rights reserved to financial investors and retail.
  • Creadev and Banque des Territoires invest in ipso santéJones Day advised Creadev SAS and Banque des Territoires in connection with an investment in ipso santé, a network of medical practices.
  • Agicap raises capital in €45 million Series C financingJones Day advised Agicap, the all-in-one Treasury management platform, in connection with its €45 million Series C financing led by AVP.
  • CARMAT completes €10.3 million share capital increaseJones Day represented CARMAT SA, the designer and developer of the world's most advanced total artificial heart listed on Euronext Growth Paris, in connection with its €10.3 million share capital increase without preferential subscription rights but with a priority right through a public offering.
  • Amolyt Pharma acquired by AstraZenecaJones Day advised Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, in its $1.05 billion acquisition by AstraZeneca.
  • CARMAT establishes equitization of its European Investment Bank debt via Fiducie-gestion structureJones Day represented CARMAT SA, the designer and developer of the world's most advanced total artificial heart listed on Euronext Growth Paris, in connection with the equitization of its debt granted by European Investment Bank via a Fiducie-gestion and the sale of shares on the market with the proceeds of the sale to be allocated in repayment of the debt.
  • Silicon Mobility sold to IntelJones Day advised Silicon Mobility SAS in the acquisition of the company by Intel Corporation.
  • Arverne Group combines with Transition to publicly list on Euronext Paris the future French leader in geothermal and low-carbon lithium to drive energy transitionJones Day advised Arverne Group SAS, a French company ("Arverne"), in its business combination with Euronext listed Transition SA to create the future French leader in geothermal and low-carbon lithium production.
  • Deezer invests to create livestreaming powerhouse as Driift acquires DreamstageJones Day advised Deezer S.A. in its £4 million investment in the merger of Driift and Dreamstage, creating a livestreaming powerhouse.
  • Deezer merges with and into I2PO S.A.Jones Day advised Deezer S.A. in the context of the SPAC transaction whereby Deezer S.A. merged with and into I2PO S.A., a French SPAC listed on the professional segment of the regulated market of Euronext Paris and the related PIPE financing.
  • Bpifrance (Large Venture) participates in $355 million Series D financing round of ExotecJones Day represented Bpifrance (Large Venture) in the $355 million Series D round of financing of Exotec, a provider of robotic solutions for warehouses, led by Goldman Sachs Asset Management, along with Bpifrance (Large Venture) and 83North, becoming the first French industrial unicorn.
    •

    Avant d’envoyer cet e-mail, veuillez prendre note de ce qui suit :

    Les informations contenues sur le site www.jonesday.com sont destinées à un usage général et ne constituent pas des conseils juridiques. L’envoi et la réception de cet e-mail n’ont pas pour effet de créer une relation avocat-client. Aucun envoi de votre part à un membre du Cabinet ne sera traité comme confidentiel ou protégé à moins que nous n’ayons donné notre accord pour vous représenter. En envoyant cet e-mail, vous confirmez avoir lu et compris la présente notification.